BioNTech In Another China ADC Deal, This Time With Medilink

HER3-Targeting Asset

 
• By Dexter Jie Yan
  
unique
BioNTech picks Medilink’s differentiated TMALIN ADC platform in HER3-targeting ADC deal • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia